Study analysis · The American journal of psychiatry · 2012
Could a common workout supplement turbocharge antidepressants for women with depression?
Adding creatine to an SSRI helped women with depression improve faster and more often than the SSRI alone.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This is like a fair test where some people get the real treatment and some get a fake one, and neither the patients nor the doctors know which is which. It shows that the real treatment helped more, so we can say it caused the improvement in these people. But it was only a few women, so we can't be sure it works for everyone.
What’s the bottom line?
Scientists wanted to see if adding a supplement called creatine to a common antidepressant helps women with depression feel better sooner and more completely. They gave half the women creatine and half a fake pill (placebo) along with their regular medication.
How strong is this study?
This study was done very carefully - it was randomized and blinded, so it's a high-quality study. But it was small and had some people drop out, so we need more studies to be really sure about the results.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
81 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=52)+4.6/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 562 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Although the randomized controlled trial design can establish causation, the small sample size, specific population (women), and relatively short duration limit the strength of causal inferences. Results may not generalize to other populations.
No Conflicts
No conflicts of interest identified
No conflicts of interest declared in the provided text; study appears to be independently conducted.
Independent Analysis Safeguards
- Double-blind design
- Randomized allocation
- Blinded outcome assessor
No conflicts of interest or funding disclosures mentioned in the provided sections. The study protocol was approved by institutional review boards. The analysis appears to be conducted independently.
Key takeaways
- 01
Women taking creatine showed more improvement in depression after 2 weeks, and more of them had a big improvement by week 2 (32% vs 4%) and week 4 (68% vs 30%).
- 02
After 8 weeks, 52% of the creatine group were much better (remission) compared to 26% in the placebo group.
- 03
This suggests creatine might make antidepressants work faster and better, but the study was small and only in women, so more research is needed.
Surprising findings
- Response rates at week 2 were 32% for creatine vs 3.7% for placebo – an 8-fold difference.Antidepressants typically take weeks to show effects; this rapid response is highly unusual.
- Remission rate nearly doubled: 52% vs 25.9% at 8 weeks.A relatively simple supplement almost doubled the rate of full recovery, which is typically hard to achieve with standard treatments.
- No significant difference in adverse events, despite creatine's known potential for gastrointestinal issues.Creatine in high doses (like 10-20g/day) often causes stomach problems, but at 5g/day, it was as tolerable as placebo.
Practical takeaways
If you're a woman with major depressive disorder and are on an SSRI, discuss with your doctor whether adding creatine (5 g/day) might be beneficial.
This is a single small study; always consult a healthcare professional before starting supplements.
medium confidenceFor clinicians: Consider creatine as an potential adjunctive treatment for patients who are not responding quickly to SSRIs.
Need to monitor renal function, as creatine can slightly raise serum creatinine.
medium confidenceFor researchers: Design larger, more diverse trials (including men and different ethnicities) with longer follow-up to confirm these findings.
Until then, consider this preliminary evidence.
high confidenceWhy this study matters
Fast Relief: Creatine's Quick Antidepressant Boost
Women taking creatine with escitalopram showed significant improvements in depression scores as early as week 2, with 32% responding versus only 3.7% on placebo. This faster onset is crucial because standard antidepressants often take weeks to work.
Patients and clinicians are desperate for faster relief from depression, which can be debilitating. A simple, widely available supplement might accelerate response.
Doubling Remission Rates with Creatine
After 8 weeks, 52% of women in the creatine group achieved remission versus only 25.9% in the placebo group, an odds ratio of 6.92. This suggests that adding creatine could nearly double the chances of full recovery for some patients.
Remission is the ultimate goal for depression treatment, and a cheap, accessible supplement might help achieve it.
Why Creatine Might Work: Brain Energy Boost
The theory is that creatine enhances the brain's energy production by replenishing ATP stores, which may be depleted in depression. Prior studies show abnormal brain bioenergetics in MDD patients, and creatine could correct this.
This gives a tangible biological mechanism, making the idea more plausible and sparking curiosity about brain energy metabolism.
Safe and Tolerable Addition
Creatine was well-tolerated, with no significant increase in adverse events or dropout rates compared to placebo. Even serum creatinine elevations were mild and stayed within normal range.
Patients often worry about side effects, so a supplement that doesn't worsen side effects is a big plus.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists wanted to see if adding a supplement called creatine to a common antidepressant helps women with depression feel better sooner and more completely. They gave half the women creatine and half a fake pill (placebo) along with their regular medication.
Research results
Women taking creatine showed more improvement in depression after 2 weeks, and more of them had a big improvement by week 2 (32% vs 4%) and week 4 (68% vs 30%). After 8 weeks, 52% of the creatine group were much better (remission) compared to 26% in the placebo group.
What this means - more context
This suggests creatine might make antidepressants work faster and better, but the study was small and only in women, so more research is needed.
To assess whether adding creatine monohydrate to the SSRI escitalopram improves and accelerates antidepressant response in women with major depressive disorder.
In a randomized, double-blind, placebo-controlled trial, 52 women with major depressive disorder received escitalopram plus either creatine (5 g/day) or placebo for 8 weeks. Creatine augmentation led to significantly greater improvements in depressive symptoms (HAM-D) as early as week 2, maintained through week 8. Response rates were higher with creatine at weeks 2 and 4, and remission at week 8 was 52% vs 25.9%. Creatine was well-tolerated with no significant differences in adverse events or discontinuation rates. Note: This study has corrections/errata; readers should check the correction notices for updated information.
Methods Used
Double-blind, placebo-controlled RCT with 52 women (25 creatine, 27 placebo) diagnosed with major depressive disorder. Participants received escitalopram (10-20 mg/day) plus creatine (5 g/day after a 3 g/day load) or placebo for 8 weeks. Primary outcome was change in HAM-D score; secondary included MADRS, CGI, response and remission rates.
Main Finding
Creatine augmentation significantly improved depressive symptoms from week 2 through week 8 compared to placebo. Response rates at weeks 2 and 4 were significantly higher (32% vs 3.7% and 68% vs 29.6%), and remission at week 8 was 52% vs 25.9% (OR=6.92). No significant differences in adverse events or dropout.
Confidence Level
Moderate: Small sample (N=52), only women, single site, short duration (8 weeks). Well-conducted double-blind RCT, but findings need replication in larger, more diverse populations.
Study Flags
Red Flags
- •Small sample size (N=52) limits statistical power
- •Only women included, limiting generalizability
- •Short duration (8 weeks) and no long-term follow-up
Surprising Findings
Response rates at week 2 were 32% for creatine vs 3.7% for placebo – an 8-fold difference.
Antidepressants typically take weeks to show effects; this rapid response is highly unusual.
Practical Takeaways
If you're a woman with major depressive disorder and are on an SSRI, discuss with your doctor whether adding creatine (5 g/day) might be beneficial.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 562 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This is like a fair test where some people get the real treatment and some get a fake one, and neither the patients nor the doctors know which is which. It shows that the real treatment helped more, so we can say it caused the improvement in these people. But it was only a few women, so we can't be sure it works for everyone.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Randomized, double-blind, placebo-controlled design
- Intention-to-treat analysis
- Multiple validated outcome measures (HAM-D, MADRS, CGI)
Weaknesses
- Small sample size (N=52)
- High dropout rate (though not significantly different)
- Only women included
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists wanted to see if adding a supplement called creatine to a common antidepressant helps women with depression feel better sooner and more completely. They gave half the women creatine and half a fake pill (placebo) along with their regular medication.
Research results
Women taking creatine showed more improvement in depression after 2 weeks, and more of them had a big improvement by week 2 (32% vs 4%) and week 4 (68% vs 30%). After 8 weeks, 52% of the creatine group were much better (remission) compared to 26% in the placebo group.
What this means - more context
This suggests creatine might make antidepressants work faster and better, but the study was small and only in women, so more research is needed.
To assess whether adding creatine monohydrate to the SSRI escitalopram improves and accelerates antidepressant response in women with major depressive disorder.
In a randomized, double-blind, placebo-controlled trial, 52 women with major depressive disorder received escitalopram plus either creatine (5 g/day) or placebo for 8 weeks. Creatine augmentation led to significantly greater improvements in depressive symptoms (HAM-D) as early as week 2, maintained through week 8. Response rates were higher with creatine at weeks 2 and 4, and remission at week 8 was 52% vs 25.9%. Creatine was well-tolerated with no significant differences in adverse events or discontinuation rates. Note: This study has corrections/errata; readers should check the correction notices for updated information.
Methods Used
Double-blind, placebo-controlled RCT with 52 women (25 creatine, 27 placebo) diagnosed with major depressive disorder. Participants received escitalopram (10-20 mg/day) plus creatine (5 g/day after a 3 g/day load) or placebo for 8 weeks. Primary outcome was change in HAM-D score; secondary included MADRS, CGI, response and remission rates.
Main Finding
Creatine augmentation significantly improved depressive symptoms from week 2 through week 8 compared to placebo. Response rates at weeks 2 and 4 were significantly higher (32% vs 3.7% and 68% vs 29.6%), and remission at week 8 was 52% vs 25.9% (OR=6.92). No significant differences in adverse events or dropout.
Confidence Level
Moderate: Small sample (N=52), only women, single site, short duration (8 weeks). Well-conducted double-blind RCT, but findings need replication in larger, more diverse populations.
Study Flags
Red Flags
- •Small sample size (N=52) limits statistical power
- •Only women included, limiting generalizability
- •Short duration (8 weeks) and no long-term follow-up
Surprising Findings
Response rates at week 2 were 32% for creatine vs 3.7% for placebo – an 8-fold difference.
Antidepressants typically take weeks to show effects; this rapid response is highly unusual.
Practical Takeaways
If you're a woman with major depressive disorder and are on an SSRI, discuss with your doctor whether adding creatine (5 g/day) might be beneficial.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 562 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Moderate probability
on the GRADE evidence scale
This is like a fair test where some people get the real treatment and some get a fake one, and neither the patients nor the doctors know which is which. It shows that the real treatment helped more, so we can say it caused the improvement in these people. But it was only a few women, so we can't be sure it works for everyone.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Randomized, double-blind, placebo-controlled design
- Intention-to-treat analysis
- Multiple validated outcome measures (HAM-D, MADRS, CGI)
Weaknesses
- Small sample size (N=52)
- High dropout rate (though not significantly different)
- Only women included
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study was done very carefully - it was randomized and blinded, so it's a high-quality study. But it was small and had some people drop out, so we need more studies to be really sure about the results.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
81 / 100
- Randomization+20/20
- Blinding+15/15
- Control group+15/15
- Sample size (n=52)+4.6/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 562 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Although the randomized controlled trial design can establish causation, the small sample size, specific population (women), and relatively short duration limit the strength of causal inferences. Results may not generalize to other populations.
No Conflicts
No conflicts of interest identified
No conflicts of interest declared in the provided text; study appears to be independently conducted.
Independent Analysis Safeguards
- Double-blind design
- Randomized allocation
- Blinded outcome assessor
No conflicts of interest or funding disclosures mentioned in the provided sections. The study protocol was approved by institutional review boards. The analysis appears to be conducted independently.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Physionic cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence